Biomerica Inc (BMRA) stock
BMRANasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 15, 2026Score 8/3047% below fair value
$1.32−0.04 (-2.94%)
Close on Nov 16, 2026Market cap $6.07MP/E –Yield –
Biomerica gross margin
Gross margin is gross profit as a percentage of revenue.
Biomerica's gross margin for the twelve months ending Aug 31, 2026 was 0.9%. For fiscal 2026 it was 8.1%, against 9.4% the year before. The highest annual figure on record is 37.8% in fiscal 2012.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | May 31, 2026 | 8.1% | −1.2 |
| FY2025 | May 31, 2025 | 9.4% | −1.9 |
| FY2024 | May 31, 2024 | 11.3% | +2.9 |
| FY2023 | May 31, 2023 | 8.4% | −7.4 |
| FY2022 | May 31, 2022 | 15.8% | +10.7 |
| FY2021 | May 31, 2021 | 5.1% | −20.9 |
| FY2020 | May 31, 2020 | 26.0% | +1.1 |
| FY2019 | May 31, 2019 | 24.8% | −6.7 |
| FY2018 | May 31, 2018 | 31.5% | −3.4 |
| FY2017 | May 31, 2017 | 34.9% | +5.3 |
| FY2016 | May 31, 2016 | 29.7% | −1.4 |
| FY2015 | May 31, 2015 | 31.1% | −1.5 |
| FY2014 | May 31, 2014 | 32.6% | −4.9 |
| FY2013 | May 31, 2013 | 37.5% | −0.3 |
| FY2012 | May 31, 2012 | 37.8% | +6.6 |
| FY2011 | May 31, 2011 | 31.1% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | 8.1% | −22.6 |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -8.1% | +24.5 |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -4.5% | −6.2 |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | 4.2% | −22.5 |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | 30.7% | +14.7 |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -32.6% | −34.4 |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | 1.7% | +16.3 |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | 26.7% | +6.0 |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | 16.0% | −8.1 |
| Q4 FY2024CQ2 2024 | May 31, 2024 | 1.8% | −0.8 |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -14.7% | −25.5 |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | 20.7% | −3.0 |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | 24.1% | +27.4 |
| Q4 FY2023CQ2 2023 | May 31, 2023 | 2.6% | −9.1 |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | 10.8% | −11.0 |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | 23.8% | +7.1 |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -3.4% | +3.7 |
| Q4 FY2022CQ2 2022 | May 31, 2022 | 11.7% | +10.5 |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | 21.8% | +23.9 |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | 16.6% | −5.9 |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -7.1% | −17.4 |
| Q4 FY2021CQ2 2021 | May 31, 2021 | 1.2% | −24.1 |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -2.0% | −20.0 |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | 22.5% | −6.9 |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | 10.3% | −20.4 |
| Q4 FY2020CQ2 2020 | May 31, 2020 | 25.3% | +9.8 |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | 18.0% | −11.0 |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | 29.4% | +2.2 |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | 30.8% | +4.3 |
| Q4 FY2019CQ2 2019 | May 31, 2019 | 15.5% | −8.2 |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | 29.0% | −4.8 |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | 27.2% | −4.2 |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | 26.5% | −9.1 |
| Q4 FY2018CQ2 2018 | May 31, 2018 | 23.7% | −6.5 |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | 33.8% | +3.9 |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | 31.4% | −7.5 |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | 35.6% | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | 30.3% | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | 30.0% | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | 38.9% | – |
See a number that looks wrong?